ArticleFrontiers in public health2025
Global, regional, and national burdens of cirrhosis in childhood and adolescence during 2000 to 2021: an age-period-cohort analysis.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cirrhosis is a major cause of morbidity and mortality worldwide, but data on the cirrhosis burden and trends in children and adolescents are sparse. Methods: Data on cirrhosis during 2000-2021, including global-, regional, and national-level numbers of cases, incidence, and prevalence, were collected by the GBD 2021 database. Trends across age groups, periods, and birth cohorts were analysed using the age-period-cohort (APC) model; epidemiological trajectories were predicted using the Bayesian APC (BAPC) model. Results: From 2000 to 2021, cirrhosis incidence decreased in the 5-9 and 10-14-year age groups but increased in the 15-19 and 20-24-year age groups. In the 15-19- and 20-24-year age groups, the respective proportion of cirrhosis due to hepatitis B decreased from 11 to 4% and from 35 to 23%, while the respective proportion due to metabolic dysfunction-associated fatty liver disease (MAFLD) increased from 87 to 93% and from 55 to 67%. Regionally, the proportion of cirrhosis attributable to HBV decreased over time, while MAFLD became the leading cause among individuals aged 15-24 years. Overall, the effects of cirrhosis among children and adolescents were consistent across socio-demographic index regions and globally, increasing with age but decreasing with period and cohort. However, the period and cohort effects of MAFLD-related cirrhosis increased regionally and globally. The BAPC model predicted that the incidence of cirrhosis among children and adolescents will continue to rise until 2050. Conclusion: During 2000-2021, the burden associated with hepatitis B declined, while the proportion of cirrhosis caused by MAFLD has been steadily increasing. The APC model revealed a consistent global trend of cirrhosis risk, increasing with age but decreasing by period and cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.